SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT07344922

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07344922
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07344922. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-01 (actual); primary completion 2023-11-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia
Condition
Anemia
Condition
Cardiovascular Calcification
Intervention (Drug)
Dapagliflozin (10Mg Tab) along with standard medical therapy
Intervention (Other)
Placebo
Lead sponsor
Mansoura University (class: other)

Record details

Record id
cardio:ct-nct07344922
Content hash
726e8c121ea47298dd7a11c7540e2067ca4febed9afa8775be97b31b65904b4c